Identification of Biomarkers for Patients With Vascular Anomalies
Status: | Recruiting |
---|---|
Conditions: | Women's Studies |
Therapuetic Areas: | Reproductive |
Healthy: | No |
Age Range: | Any |
Updated: | 3/23/2019 |
Start Date: | April 2015 |
Contact: | Timothy LeCras, PhD |
Email: | hvmcresearch@cchmc.org |
Phone: | 5138034862 |
The study will use blood (serum and plasma) and tissue obtained from participants undergoing
prescribed surgical resection of vascular anomalies of interest proposed in this study. The
study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank
maintained by the Department of Hematology/Oncology.
prescribed surgical resection of vascular anomalies of interest proposed in this study. The
study will also use blood (serum and plasma) and tissue collected and stored in a tissue bank
maintained by the Department of Hematology/Oncology.
While vascular anomalies are rare diseases, they can be life-threatening and devastating to
affected children and their families. Advances in diagnosis, monitoring and therapies will be
significantly improved if non-invasive biomarkers that are sensitive and specific can be
identified. Obtaining a tissue biopsy to help in diagnosis can actually worsen the disease
and so identification of specific blood biomarkers is highly desirable. Studies will measure
angiogenic factors in serum and plasma samples at baseline and on therapy. Tissue removed
during surgical resection or blood removed prior to sclerotherapy will be used to obtain
cells and tissue for the assessment of where biomarkers are coming from and to identify
disease-causing pathways for new therapeutic targeting.
affected children and their families. Advances in diagnosis, monitoring and therapies will be
significantly improved if non-invasive biomarkers that are sensitive and specific can be
identified. Obtaining a tissue biopsy to help in diagnosis can actually worsen the disease
and so identification of specific blood biomarkers is highly desirable. Studies will measure
angiogenic factors in serum and plasma samples at baseline and on therapy. Tissue removed
during surgical resection or blood removed prior to sclerotherapy will be used to obtain
cells and tissue for the assessment of where biomarkers are coming from and to identify
disease-causing pathways for new therapeutic targeting.
Inclusion Criteria:
- Any patient having labs drawn as standard of care will have blood drawn for the study
if consented/ assented.
- All patients who are undergoing a surgical procedure or sclerotherapy are currently
consented for participation in the tissue bank.
Exclusion Criteria:
We found this trial at
2
sites
300 Longwood Ave
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Denise Adams, MD
Phone: 617-355-2901
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
Cincinnati, Ohio 45229
1-513-636-4200
Principal Investigator: Timothy LeCras, PhD
Phone: 513-803-4862
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
Click here to add this to my saved trials